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In the initial phase of heart failure, cardiac output and pressure are maintained by increasing sympathetic drive and by cell
hypertrophy. Elevated end-diastolic volume, a reduced ejection fraction and a higher filling pressure also occur. Only in
more severe heart failure, when cardiac output cannot be maintained, do symptoms appear which may vary between con-
gestion, exercise intolerance, left ventricular dysfunction, arrhythmias or a combination of each.
Drug treatment has principally two aims: first, to improve symptoms, second, to influence prognosis, which is very poor
in advanced heart failure. Symptom improvement will also depend on whether the condition is acute, subacute or chronic
heart failure. In the acute situation diuretics are normally the first choice of treatment, whereas in chronic heart failure the
ACE inhibitors have proved themselves to be the drugs which most improve prognosis. The role of digitalis, still frequently
used, remains unclear, and its importance will be revealed when the results of ongoing studies are announced.
When contractility decreases or some myocardial fibres are
lost due to necrosis, the organism has to compensate in
order to maintain a normal circulation. In this initial phase
of heart failure, metabolic demands and necessary perfu-
sion pressure are maintained by the heart and circulation
by increasing sympathetic drive and cell hypertrophy.
Catecholamines lead to an increase in heart rate, by stimu-
lation of renin-angiotensin, to sodium retention and thus to
volume elevation and finally to vasoconstriction of the
smaller vessels. When the diastolic volume of the ventricles
increases, the contractile force of muscle fibres is enhanced
according to Frank-Starling's law. In an early phase of
heart failure we have, therefore, normal cardiac output at
rest and under moderate exercise, but with a slightly
increased heart rate, a higher than normal end-diastolic
volume and therefore reduced ejection fraction, and an
elevated filling pressure. In this situation, the patient has
very few, if any, symptoms and only if effort tolerance is
measured is a reduction in the maximal work load and in
oxygen uptake found.
In more severe heart failure, normal cardiac output can-
not be maintained and in order to guarantee an acceptable
perfusion pressure, especially for the brain, the kidneys,
and the heart, peripheral vasoconstriction occurs. With this
elevated resistance, pressure can be maintained at an
acceptable level, but at the cost of an increased work load
on the failing heart. Volume retention and left ventricular
end-diastolic pressure increases, leading finally to pul-
monary congestion and, if the right heart also fails, to
peripheral oedema. A low cardiac output also results in a
reduced perfusion, not only of the skin and the intestines
but also of the kidneys, leading to pre-renal failure, and to
exercise intolerance of the muscles. Dilation of the heart,
as well as hypertrophy, enhance ventricular ectopic activity
which may become the dominant symptom. Figure 1
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demonstrates the different states that patients with the
clinical syndrome of heart failure may show.
Drug treatment has principally two aims: first, to
improve symptoms and with that quality of life; secondly,
to improve prognosis, which is very poor once severe symp-
toms are present. From Figure 1 it becomes evident that
drug treatment to improve symptoms depends on the clin-
ical picture of the patient. This therapy may vary from that
used to improve prognosis. In addition, drugs have differ-
ent aims in the acute as compared to the chronic situation.
In acute heart failure, improvement in haemodynamics is
the most important issue. Diuretics and vasodilators lower
diastolic volume and pressure, improving dyspnoea and
peripheral oedema. In patients with acute breathlessness,
diuretics are very often the drug of first choice.
Comparative studies, however, have shown that with
vasodilators a similar reduction of preload can be reached
with less depression of cardiac output, which often occurs
under diuretic treatment alone'1!.
In the subacute situation, it is important to increase
exercise tolerance by improving cardiac output, and
here it seems that digitalis is still an important drug.
Phosphodiesterase inhibitors, on the other hand, despite
their beneficial haemodynamic effect, are no longer used
due to their deleterious effect on prognosis. Here, improve-
ment by drug treatment should be measured by effort tol-
erance tests, by measuring maximal oxygen uptake, and
perhaps by questionnaires about quality of life.
In the chronic situation, improvement of left ventricular
function, of neurohormonal status and of prognosis
becomes the most important goal. It seems that the drugs
of choice are ACE inhibitors. In the Veterans
Administration Heart Failure Trial II (V-HeFT II) study
Cohn and co-workers could demonstrate that the change in
peak oxygen consumption and in ejection fraction was
more pronounced with a combination of hydralazine and
isosorbide dinitrate, whereas prognosis in these same
patients was better in the enalapril-treated group121. This
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Figure 1 Clinical syndrome of heart failure.
study demonstrates that there may well be a difference in
improving symptoms compared to prognosis. Large trials
in recent years with ACE inhibitors showed that not only
patients with severe symptoms (New York Heart
Association classification class III to IV) have a better
prognosis with this treatment131. Patients with asympto-
matic left ventricular dysfunction demonstrated a reduced
morbidity and mortality compared to those who did not
receive this drug14-5'. In a substudy of the Studies of Left
Ventricular Function (SOLVD) trial it could be demon-
strated that under ACE inhibition, ventricular enlarge-
ment could be reversed for the first 2 years after start of
treatment. In the third year, the control end-diastolic vol-
ume was again reached, but the placebo group had demon-
strated a continuous enlargement of the ventricle at the
same time161. These data suggest that it is more important to
decrease end-diastolic volume than improve cardiac con-
tractility.
It is now generally accepted that the presence of com-
plex arrhythmias worsens prognosis of patients in heart
failure. Despite the fact that with class III antiarrhythmic
drugs we may improve prognosis after myocardial infarc-
tion171 this does not seem to be possible when left ventricu-
lar function is severely depressed1851.
For the individual patient, therefore, we have to consider
all these different facts In severe left ventricular dysfunc-
tion, an ACE inhibitor is needed to improve prognosis. In
patients with symptoms of congestion a diuretic has to be
added and in those where effort intolerance dominates,
a combination of ACE inhibitor with digitalis and/or
vasodilators may be preferable.
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